---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056256"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:18:58.103825+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio reports Q1 2024 results; cash $135.3M, pipeline on track

## Summary
- Cash, equivalents, and short-term investments of $135.3M as of March 31, 2024; funding into mid-2026.
- Completed enrollment in bempikibart Phase 2 alopecia areata trial; topline results expected Q4 2024.
- ADX-097 renal basket Phase 2 trial to start H1 2024; initial data expected by year-end 2024.
- Reverse merger with Homology Medicines closed in March 2024; concurrent $42M private placement.
- Net income of $1.0M due to $15.9M gain on convertible note conversion; R&D expense $9.8M.

## SEC filing metadata
- accession: 0000950170-24-056256
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000095017024056256/0000950170-24-056256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000095017024056256/qttb-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056256
- JSON: https://secwatch.observer/filing/0000950170-24-056256.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056256.txt

## Key facts
- Earnings Releases
  Q32 Bio Inc. reported the quarter ended March 31, 2024 results: net income $1.0 million, EPS $1.03 basic net income per share and ($6.33) diluted net loss per share.
  - Period: the quarter ended March 31, 2024
  - Net income: $1.0 million
  - EPS: $1.03 basic net income per share and ($6.33) diluted net loss per share
  - Result: reported results
  source text: Q32 Bio Inc. announced its financial results for the quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000095017024056256/0000950170-24-056256-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.